Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Apr;7(4):590-594.
doi: 10.1002/acn3.51026. Epub 2020 Apr 3.

Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy

Martina Romagnoli  1 , Chiara La Morgia  1   2 , Michele Carbonelli  1 , Lidia Di Vito  1 , Giulia Amore  2 , Corrado Zenesini  1 , Maria Lucia Cascavilla  3 , Piero Barboni  3   4 , Valerio Carelli  1   2
Affiliations
Observational Study

Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy

Martina Romagnoli et al. Ann Clin Transl Neurol. 2020 Apr.

Abstract

We previously documented that idebenone treatment in OPA1-Dominant Optic Atrophy (OPA1-DOA) led to some degrees of visual improvement in seven patients. We here present the results of a cohort study, which investigated the effect of off-label idebenone administration in a larger OPA1-DOA group compared with untreated patients. Inclusion criteria were: OPA1-DOA clinical and molecular diagnosis, baseline visual acuity (VA) greater than/equal to counting fingers and treatment duration greater than 7 months. We found a significant difference between the last visit and baseline VA in favor of stabilization/recovery in idebenone-treated as compared to untreated patients. This effect was retained after controlling for confounders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest related to the content of this article.

Figures

Figure 1
Figure 1
OPA1‐DOA visual acuity outcome between baseline and last follow‐up visits. Three possible scenarios of VA outcome are shown by way of example: recovery (1); stabilization (2a and 2b) and worsening (3). The VA outcome of interest for statistical analysis was the VA stabilization/recovery, defined as a best‐corrected‐visual acuity change (VA change). VA = best‐corrected‐visual acuity in logMAR unit.
Figure 2
Figure 2
Visual acuity outcome in untreated and idebenone‐treated OPA1‐mutant DOA patients. Panels A and B show cumulative frequency graphs of untreated (A) and idebenone‐treated (B) OPA1‐DOA patients based on their categorical VA outcome. Light‐blue area represents stable/recovery patients, while pink area corresponds to worsening subgroup of patients. The percentage of idebenone stable/recovery (2B: 92%, n = 46) resulted significantly greater than the untreated (2A: 75.7%, n = 28) by more than 15% (Chi‐square test, P = 0.03). Panel C shows VA change box plot with a solid line representing median value and dotted line representing mean value for both groups. VA = best‐corrected‐visual acuity in logMAR unit; BS = baseline; LV = last visit.
See this image and copyright information in PMC

References

    1. Klopstock T, Yu‐Wai‐Man P, Dimitriadis K, et al. A randomized placebo‐controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134(Pt 9):2677–2686. - PMC - PubMed
    1. Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011;134(Pt 9):e188. - PubMed
    1. Barboni P, Valentino ML, La Morgia C, et al. Idebenone treatment in patients with OPA1‐mutant dominant optic atrophy. Brain 2013;136(Pt 2):e231. - PubMed
    1. Carelli V, Ross‐Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23:53–89. - PubMed
    1. Yu‐Wai‐Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies ‐ disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81–114. - PMC - PubMed

Publication types

MeSH terms